Treating asthma with omega-3 fatty acids: where is the evidence? A systematic review by Reisman, J et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Complementary and 
Alternative Medicine
Open Access Research article
Treating asthma with omega-3 fatty acids: where is the evidence? A 
systematic review
J Reisman*1, HM Schachter2, RE Dales3, K Tran4, K Kourad2, D Barnes2, 
M Sampson2, A Morrison4, I Gaboury2 and J Blackman5
Address: 1Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, 2Chalmers Research Group, Children's Hospital 
of Eastern Ontario Research Institute, Ottawa, ON, Canada, 3The Clinical Epidemiology Unit, Ottawa Health Research Institute, Ottawa Hospital 
and University of Ottawa, Ottawa, ON, Canada, 4Canadian Coordinating Office for Health Technology Assessment, Ottawa, ON, Canada and 
5Complementary Medicine Program, University of Maryland, Baltimore, MD, USA
Email: J Reisman* - jreisman@cheo.on.ca; HM Schachter - hschachter@cheo.on.ca; RE Dales - rdales@ohri.ca; K Tran - khait@ccohta.ca; 
K Kourad - kkourad@cheo.on.ca; D Barnes - dbarnes@cheo.on.ca; M Sampson - msampson@cheo.on.ca; A Morrison - andram@ccohta.ca; 
I Gaboury - igaboury@cheo.on.ca; J Blackman - infocenter@chh.org
* Corresponding author    
Abstract
Background:  Considerable interest exists in the potential therapeutic value of dietary
supplementation with the omega-3 fatty acids. Given the interplay between pro-inflammatory
omega-6 fatty acids, and the less pro-inflammatory omega-3 fatty acids, it has been thought that the
latter could play a key role in treating or preventing asthma. The purpose was to systematically
review the scientific-medical literature in order to identify, appraise, and synthesize the evidence
for possible treatment effects of omega-3 fatty acids in asthma.
Methods: Medline, Premedline, Embase, Cochrane Central Register of Controlled Trials, CAB
Health, and, Dissertation Abstracts were searched to April 2003. We included randomized
controlled trials (RCT's) of subjects of any age that used any foods or extracts containing omega-
3 fatty acids as treatment or prevention for asthma. Data included all asthma related outcomes,
potential covariates, characteristics of the study, design, population, intervention/exposure,
comparators, and co interventions.
Results: Ten RCT's were found pertinent to the present report.
Conclusion: Given the largely inconsistent picture within and across respiratory outcomes, it is
impossible to determine whether or not omega-3 fatty acids are an efficacious adjuvant or
monotherapy for children or adults. Based on this systematic review we recommend a large
randomized controlled study of the effects of high-dose encapsulated omega-3 fatty acids on
ventilatory and inflammatory measures of asthma controlling diet and other asthma risk factors.
This review was limited because Meta-analysis was considered inappropriate due to missing data;
poorly or heterogeneously defined populations, interventions, intervention-comparator
combinations, and outcomes. In addition, small sample sizes made it impossible to meaningfully
assess the impact on clinical outcomes of co-variables. Last, few significant effects were found.
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Background
Asthma is one of the most common chronic conditions,
and affects both adults and children. Its prevalence has
been noted to have increased significantly in Western
nations with overall prevalence rates ranging from 7–15%
[1]. The National Heart, Lung, and Blood Institute
(NHLBI) has defined asthma as a chronic inflammatory
disease of the airways[2].
The inflammatory response is complex, and involves a
variety of inflammatory cell types including mast cells,
alveolar macrophages, neutrophils, eosinophils, lym-
phocytes, platelets, and a variety of inflammatory media-
tors[3,4]. Over time, various therapeutic strategies have
been developed to manage asthma, including the use of
short acting beta-2 agonist bronchodilator medications as
symptom relievers and anti-inflammatory preventer med-
ications such as inhaled corticosteroids and oral leukot-
riene antagonists[2,5]. Given that the cause of airway
inflammation can be multifactorial and involves a multi-
tude of cell types and inflammatory mediators, the medi-
cations used to control inflammation may act at several
different points in the inflammatory pathway[2,5].
Despite many therapeutic advances over the last thirty
years, asthma continues to result in significant childhood
and adult morbidity[5].
Given the rapidity of the increase in asthma's prevalence,
environmental factors rather than increased genetic sus-
ceptibility are more likely to be responsible for this trend.
Thus, there has been increased interest in investigating
various environmental factors that may contribute to this
illness, including diet. McKeever and Britton recently con-
cluded that the trial evidence is less conclusive about the
protective effects of fish oil intake on asthma and/or
allergy than is the observational evidence[1]. There has
been considerable interest in the potential therapeutic
and protective value of dietary supplementation with the
omega-3 fatty acids. Horrobin hypothesized that the low
incidence of asthma in the northern aboriginal popula-
tion stems from their consumption of large quantities of
oily fish rich in omega-3 fatty acids[6]. Moreover, given
the competitive interplay (e.g., for enzymes in the meta-
bolic pathway and for positions in cell membranes)
between pro-inflammatory omega-6 fatty acids, which
may contribute to the cascade of events marking asthma,
and the less pro-inflammatory omega-3 fatty acids, it has
been thought that the latter could play a key role in treat-
ing or preventing asthma[7]. From this perspective, respi-
ratory benefits might be attributable to changes in the
status of mediators of inflammation such as leukotrienes
and prostaglandins.
A systematic review was conducted to review the scientific-
medical literature to identify, appraise and synthesize the
evidence regarding the possible treatment and preventive
value of omega-3 fatty acids in asthma[8]. This report
describes the randomized controlled study (RCT) evi-
dence concerning the efficacy of the treatment of asthma
with omega-3 fatty acid supplementation in adult or pedi-
atric populations. In addition to determining whether this
intervention improves respiratory outcomes, its impact
on the mediators of inflammation thought to be relevant
to the pathogenesis of asthma is evaluated with this RCT
evidence. Safety data are also presented.
Methods
A comprehensive search for citations was conducted in
April 2003 using six databases (MEDLINE, PreMEDLINE,
EMBASE, Cochrane Central Register of Controlled Trials,
Commonwealth Agriculture Bureau Health [CAB Health],
and Dissertation Abstracts). All databases were searched
via the Ovid interface using Search Strategy 1, except CAB
Health which was searched through Silver Platter using
Search Strategy 2 (See Additional file 1).
Searches were not restricted by language of publication,
publication type, or study design except with the MeSH
term "dietary fats," which was limited by study design to
increase its specificity. Search elements included: scientific
terms, with acronyms, as well as generic and trade names
relating to the exposure and its sources (e.g., eicosapentae-
noic acid [EPA]; MaxEPA®; fish oil); and relevant popula-
tion terms (e.g., asthma; inflammation). Additional
published or unpublished literature was sought through
manual searches of reference lists of included studies and
key review articles, and from the files of content experts. A
final set of 1,010 unique references was identified and
posted to an Internet-based software system for review.
Studies were considered to be relevant if they described
human populations of any age, involved any type of study
design, and investigated the use of any foods or extracts
known to contain omega-3 fatty acids from any source
(e.g., marine; plant) or of any type (e.g., EPA; alpha lino-
lenic acid acid [ALA]) or dose, and used as a treatment or
prevention. These eligibility criteria distinguish our work
from that of a recent Cochrane review, which exclusively
focused on the role of fish oil[9]. For the purposes of this
report, however, only treatment RCT's are described
because this research design is considered the gold stand-
ard for investigating questions of treatment efficacy or
effectiveness[10,11]. Populations in treatment studies
had to have received a formal diagnosis of asthma. Studies
where an asthmatic response was experimentally induced
in non-asthmatic populations were excluded. Methods
had to have been employed in primary studies to identify
the omega-3 fatty acid intervention/exposure. Studies
investigating "polyunsaturated fatty acids" or specific
diets were included if explicit reference was made to theirBMC Complementary and Alternative Medicine 2006, 6:26 http://www.biomedcentral.com/1472-6882/6/26
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omega-3 fatty acid content. A treatment study could assess
respiratory outcomes, data concerning mediators of
inflammation, or adverse effects. Forced expiratory vol-
ume in 1 second (FEV1) was selected as the primary out-
come, given its status as a gold standard index of
pulmonary function for asthma.
Two levels of screening for relevance, and two reviewers
per level, were employed (bibliographic records, then full
articles) following calibration exercises. Disagreements
were resolved by forced consensus and if needed, third
party intervention. Following a calibration exercise, three
reviewers independently abstracted the contents of each
included study using an electronic form. A second abstrac-
tor verified all data, which included outcomes (i.e., respi-
ratory, mediators of inflammation, safety;
discontinuations), potential covariates (e.g., fatty acid
content of blood lipid biomarkers, tissue ratios of fatty
acid during the investigative period), in addition to the
characteristics of the report (e.g., publication status),
study (e.g., sample size; design), population, interven-
tion/exposure (e.g. omega-3 fatty acid types and sources;
intervention length), comparators (e.g., placebo), and co
interventions (e.g. asthma medications, omega-6 fatty
acids). Dual-assessor evaluations of RCTs' quality
employed Jadad's validated items concerning randomiza-
tion, double blinding, and the reporting of withdrawals
and dropouts,[12] and b) Schulz's validated question con-
cerning the adequacy of allocation concealment[13]. A
total Jadad score below 3 (out of 5) indicates low study
quality. Select items from a third validated instrument
permitted the assessment of the quality of other designs,
which are excluded from the present report[14]. The
applicability, or generalizability, of a study to a broad-
based North American population was determined by the
degree to which the study population included asthma
patients who were otherwise "healthy," potentially exhib-
iting asthma concomitants (e.g., atopy), representing a
somewhat broad demographic spectrum (e.g., sex, ethnic-
ity), living a "typical" North American lifestyle, possibly
receiving "typical" asthma treatment, and failing to
exhibit major co morbidity.
Results
Of the 1,010 bibliographic records entered into the initial
screening for relevance, 851 were excluded. All but 5 of
the remaining 159 reports were then retrieved and sub-
jected to a more rigorous relevance assessment. The sec-
ond relevance screening then excluded 122 reports. In
total, 31 reports, describing 26 unique studies, were
deemed relevant for the systematic review of treatment or
prevention evidence, with 5 studies each described by two
reports. Nineteen treatment studies were identified, ten of
which were RCTs pertinent to the present report (Table 1)
[15-24]. Two treatment RCTs employed a crossover
design[15,21].
Nine treatment studies employed other designs, and
seven studies investigated the possible primary preventive
value of omega-3 fatty acid intake. The ten treatment RCTs
were described in 13 reports. Hodge et al.'s pediatric trial
results[17] were first disseminated as an abstract [25] Kir-
sch et al.'s adult treatment RCT had its clinical outcome
data reported in one publication[22] and its mediators of
inflammation data in another[26]. The lead author
(Jonathan Arm) of two study reports with overlapping
data recommended to us that, to avoid entering duplicate
data into our review, we should consult the first
report[18] for all data other than allergen-challenge
results, which should be obtained from the second docu-
ment[27]. To simplify matters, only one document per
study is referred to in this report's text or table. Only one
treatment RCT was not described by at least one published
report[15]. All treatment RCT reports were published in
English.
Two trials exclusively randomized children,[16,17] one
included both older adolescents and adults,[18] and the
remainder randomized adults [15,19-24]. One report did
not identify the age of its participants[24]. Given the dif-
ferences in the clinical pictures of adult and (especially
young) children's asthma, results obtained from studies
enrolling the different populations were not combined.
Given the largely inconsistent picture within and across
respiratory outcomes, it is impossible to conclude one
way or another whether omega-3 fatty acids are an effica-
cious adjuvant or monotherapy in improving respiratory
outcomes in asthmatic adults or children. This is perhaps
best illustrated by what was observed with respect to the
primary outcome variable, FEV1.
The adult RCTs revealed a somewhat contradictory picture
of efficacy with respect to FEV1. One very small adult study
conducted by Okamoto et al.(n = 14), which compared
"uncontrolled dosing" of perilla seed oil (i.e., pourable
oil) and similarly uncontrolled dosing of corn oil over a
short intervention period (4 weeks), reported a significant
positive clinical effect[19]. However, two RCTs each
observed no benefit. Kirsch et al.'s RCT compared high
and low doses of EPA ethyl ester over 8 weeks in a small
study (n = 12),[22] whereas Emelyanov investigated the
impact of low dose EPA+DHA (versus an olive oil pla-
cebo) over 8 weeks in the systematic review's highest qual-
ity RCT[23]. The latter study also randomized the second
largest sample population (n = 46) included in our evi-
dence review. Investigation of additional clinical out-
comes for adults revealed that a) for AM peak expiratory
flow (PEF), two studies reported a significant benefit,B
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Table 1: RCT Evidence of Omega-3 Fatty Acids to Improve Respiratory Outcomes in Asthma
Study groups1
Author, Year, Location: Length & 
Design
Group 1 (n)/Group 4 (n) Group 2 (n)/Group 3 (n) Jadad Total Quality/Allocation 
Concealment (Internal Validity)
Applicability
ADULTS
Arm, 1988[18] England: 10-wk parallel 
RCT
3.2 g/d EPA + 2.2 g/d DHA (n = NR) Olive oil placebo (dose: NR) (n = NR) 4/Unclear III
Emelyanov, 2002[23] Russia: 8-wk parallel 
RCT
200 mg/d EPA/DHA + 400 mg/d olive oil (n 
= 23)
600 mg/d olive oil placebo (n = 23) 5/Unclear III
Kirsch, 1988[22] USA: 8-wk parallel RCT 4.0 g/d EPA ethyl ester (+ trace DHA) (n = 
6)
0.1 g/d EPA ethyl ester (+ trace DHA) (n = 
6)
3/Unclear I
McDonald, 1991[15] Australia: 10-wk 
crossover RCT
2.7 g/d EPA + 1.8 g/d DHA (n = 15) 15 g/d olive oil placebo (n = 15) 3/Unclear III
Okamoto, 2000[19] Japan: 4-wk RCT 10–20 g/d perilla seed oil (ALA: NR) (n = 
7)
10–20 g/d corn oil (n = 7) 2/Unclear III
Stenius-Aarniala, 1989[21] Finland: 10-wk 
crossover RCT
20 mL/d fish oil (EPA+DHA: NR) (n = 36) 20 mL/d olive oil (n = 36)/20 mL/d evening 
primrose oil (n-6) (n = 36)
2/Unclear III
Thien, 1993[20] England: 26-wk parallel 
RCT
3.2 g/d EPA + 2.2 g/d DHA (n = NR) Olive oil placebo (dose: NR) (n = NR) 4/Unclear III
CHILDREN
Hodge, 1998[17] Australia: 26-wk parallel 
RCT
0.72 g/d EPA 0.48 g/d DHA + ALA (dose: 
NR) via canola diet (n = NR)
n-6: 1.8 g/d safflower oil + 1.8 g/d palm oil 
+ 0.4 g/d olive oil + sunflower diet (dose: 
NR) (n = NR)
3/Unclear III
Nagakura, 2000[16] Japan: 10-mo parallel 
RCT
17.0–26.8 mg/kg/d EPA; 7.3–11.5 mg/kg/d 
DHA (300 mg/d fish oil) (n = 15)
300 mg/d olive oil placebo (n = 15) 4/Unclear III
AGE NOT REPORTED
Dry, 1991[24] France: 9-mo parallel RCT 1.0 g/d EPA+DHA (n = NR) "Placebo" (type & dose: NR) (n = NR) 2/Unclear X
1Proceeding from highest omega-3, or lowest omega-6/omega-3, fatty acid content of intervention; n-6 = omega-6 FAs; ALA = alpha linolenic acid; DHA = docosahexaenoic acid; EPA = 
eicosapentaenoic acid; Length = intervention length; Design = research design; n = sample size; pts = study participants; NR = not reported; wk = week(s); mo = month; RCT = randomized 
controlled trial; Jadad total quality score = /5; Applicability I = greatest applicability to North American population of asthma patients; Applicability II = somewhat narrow applicability; Applicability III 
= very narrow applicability; Applicability X = insufficient data to determine applicabilityBMC Complementary and Alternative Medicine 2006, 6:26 http://www.biomedcentral.com/1472-6882/6/26
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[19,23]while three reported no benefit,[18,20,21,23]
whereas b) five studies failed to observe a significant ben-
efit for PM PEF. Inconsistent results were observed with
respect to each of three self-reported outcomes, including
bronchodilator use, asthma symptom scores and asthma
severity ratings. With regard to pediatric studies, one RCT
observed no benefit with respect to FEV1[17]. There were
too few pediatric studies with which to observe any con-
sistent patterns of result for any outcome.
No study, either involving adults or children, received an
allocation concealment rating other than "Unclear." Only
two adult studies,[19,21] in addition to the RCT for which
age data were not provided,[24] were found to exhibit low
(total Jadad score: <3) study quality. There was very lim-
ited generalizability to a broad spectrum North American
population of asthmatics for all but one of the studies,
which was conducted in the United States[22].
Several key observations made it inappropriate to con-
sider conducting meta-analysis, including missing data
(e.g., sample sizes; type and dose of omega-3 fatty acids;
types and doses of concurrent asthma medication with the
potential to confound results; placebo contents), poorly
or heterogeneously defined populations (e.g., age, exact
diagnosis, asthma severity, asthma triggers or concomi-
tants), interventions (e.g., sources, types i.e. pharmaceuti-
cal versus health-food store grade fish oil, doses, and the
degree of control over dosing of omega-3 fatty acids [cap-
sules versus pourable oils]), intervention-comparator
combinations, and outcomes. Some of the published
studies used peak flow rate as their primary outcome
measure, rather than the more reliable FEV1. In addition
to typically small sample sizes, these study limitations
also made it impossible to meaningfully assess, even qual-
itatively, the impact on clinical outcomes of co variables
such as the source, type and dose of omega-3 fatty acids.
This objective was further complicated by the fact that few
significant effects were found. These study limitations
likewise made it impossible to ascertain, based on four
adult trials[18,19,21,22] and one pediatric RCT,[17]
whether omega-3 fatty acids consistently and positively
influence the lipid mediators of inflammation in ways
congruent with the biological model implicating the
lipoxygenase and cyclooxoygenase pathways in asthma.
Six of eight adult RCTs[15,18,20-23] and the two pediatric
trials[16,17] each reported safety data. Most of the adverse
events were related to the capsule delivery of oils, rather
than to the oils per se[15,16,18,20]. On several occasions,
difficulty swallowing capsules led to a withdrawal from
the study. In two studies, participants may have had diffi-
culties swallowing 18 capsules of oil per day, yet these dif-
ficulties were not reported[18,20]. The single most serious
reaction noted was an undefined number of episodes of
nausea and vomiting after ingesting fish oil capsules,
which in turn led to study withdrawal[20]. There were
unspecified numbers of children and adults who experi-
enced mild gastrointestinal upset, yet not all of these indi-
viduals had received the omega-3 fatty acid exposure.
Fishy tasting eructations were reported by some study par-
ticipants.
Discussion
Although the use of omega-3 fatty acid supplementation
is popular and its purported beneficial effects are biologi-
cally plausible, the existing body of evidence from clinical
trials does not provide strong support for its clinical effec-
tiveness. The adverse effects of nausea and abdominal dis-
comfort do however appear to be consistent across studies
and appear to be dose-related. There is no consistent evi-
dence supporting an improvement in objective measures
of ventilatory lung function in adults with the majority of
studies of FEV1[19,22,23] and PEF [18-21,23] failing to
find a benefit of omega-3 fatty acid supplementation.
More often than not, other outcomes such as asthma
symptoms, clinical severity scores, and 'rescue inhaler use'
did not significantly improve. No RCT's, which investi-
gated non-marine sources of omega-3 fatty acids, were
found. In only the study by Hodge et al, was dietary
manipulation of n-3 PUFA performed as part of the treat-
ment phase[17]. While potential changes to mediator
generation may not be as marked with dietary manipula-
tion as compared to supplement administration, an
acceptable food-based approach may be better tolerated
by individuals in the long run, should benefit be ulti-
mately proven.
Since this systematic review has been completed, an addi-
tional study has been published that would have met our
eligibility criteria[28]. Mickleborough and co-workers
have studied the protective effect of fish oil supplementa-
tion on exercise-induced bronchoconstriction (EIB) in 16
adult asthmatic patients. Those whose diet was supple-
mented with fish oil had improved pulmonary function
to below the diagnostic EIB threshold in post-exercise
FEV1, a reduced fall in FEV1 15 minutes post exercise,
reduced bronchodilator requirement, and a reduction of a
variety of inflammatory mediators. The authors con-
cluded that fish oil might represent a possible non-phar-
macologic therapeutic strategy for asthmatic subjects with
EIB. However, this observation does not alter our own
overall conclusions[28].
The inability, due to strong inter-study clinical heteroge-
neity (i.e., populations; interventions; outcomes), to com-
bine the results in a formal meta-analysis reduces the
effective sample size from which to discern benefits or
harm. It is not possible to determine if differences in clin-
ical benefit between studies was caused by differences inBMC Complementary and Alternative Medicine 2006, 6:26 http://www.biomedcentral.com/1472-6882/6/26
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characteristics of the study groups, interventions or out-
comes, or simply due to chance. To clarify this, large ran-
domized clinical trials are needed. A daily intervention of
at least 3 grams of omega-3 fatty acids, which is consid-
ered a high adult dose, may well be required. Its source
(e.g. marine, plant) and constituents (i.e., ALA, EPA,
EPA+DHA) need to be well defined, although it is as yet
unclear which combinations of omega-3 fatty acids
should be employed. Not only should omega-3 supple-
mentation be studied, but also dietary manipulation.
Duration of intervention, minimal effective dosage, and
formulation will need to be determined. Outcomes
should reflect the dimensions of asthma; symptoms, use
of rescue inhaler, ventilatory function, variability in func-
tion, and acute exacerbations. Exhaled nitric oxide is a
newer measure of asthma inflammation. Exhaled breath
condensate could be collected and tested for leukotrienes
and prostaglandins, mediators of inflammation poten-
tially influenced by omega-3 fatty acids. Induced sputum
techniques could also be utilized to assess airway inflam-
matory cell and mediator characteristics.
Many sources of influencing and potentially confounding
variables need to be controlled in the study design, meas-
ured during the study and perhaps adjusted for in the
analysis.
Age and gender influence asthma severity and prevalence
of atopy. Co-existing anti-inflammatory medications may
overwhelm a similar but lesser effect of omega-3 fatty
acids. Dietary omega-6 fatty acids need to be controlled
for since they may compete with omega-3 fatty acids for
enzymes and positions in cell membranes and neutralize
the effect. Using encapsulated rather than pourable oils
would add precision to the dose of omega-3 fatty acid sup-
plementation. A relatively long follow-up period of one or
two years would facilitate the assessment of exacerbation
rates. Changes in exposure to indoor allergens and irri-
tants may also influence asthma control. In conclusion,
given the data available to date, and despite an acceptable
safety profile, a recommendation as to whether omega-3
fatty acids are a viable treatment modality is at present
unresolved. Recommendations for future research follow
directly from observations of the problems and limita-
tions observed in the included studies.
Conclusion
Given the largely inconsistent picture within and across
respiratory outcomes, it is impossible to determine
whether or not omega-3 fatty acids are an efficacious adju-
vant or monotherapy for children or adults. Based on this
systematic review we recommend a large randomized con-
trolled study of the effects of high-dose encapsulated
omega-3 fatty acids on ventilatory and inflammatory
measures of asthma controlling diet and other asthma risk
factors. This review was limited because Meta-analysis was
considered inappropriate due to missing data; poorly or
heterogeneously defined populations, interventions,
intervention-comparator combinations, and outcomes. In
addition, small sample sizes made it impossible to mean-
ingfully assess the impact on clinical outcomes of co-vari-
ables. Last, few significant effects were found.
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